CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the unaudited financial results for the quarter ended on June 30, 2019.09-08-2019
09-08-2019
CADILA HEALTHCARE LTD. - 532321 - Outcome of Board Meeting
Unaudited Financial Results for the quarter ended on June 30, 2019 along with Limited Review Report.09-08-2019
Cadila Healthcare Ltd - 532321 - Announcement Under Regulation 30 - Updates
U. S. FDA classifies the inspection of the Company's Moraiya unit as OAI07-08-2019
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificates02-08-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Announces Completion of Phase III trials of Saroglitazar Magnesium in Type 2 Diabetes Mellitus02-08-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Change in Directorate
Cessation of Mr. H. Dhanrajgir as a Director of the Company.31-07-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor interaction through a conference call at 4.30 p.m. on August 9, 2019.31-07-2019
Cadila Healthcare Ltd - 532321 - USFDA Inspection Ankleshwar Unit I And II
USFDA inspected the Company's API manufacturing facility located at Ankleshwar from 22nd to 26th July, 2019. This audit covered both Unit I and II. At the end of the inspection, no observation (483) is issued.26-07-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus has launched Ramelteon Tablets in the US upon receiving final approval from the USFDA24-07-2019
Company news: Cadila Healthcare
Cadila Healthcare on Friday informed the exchanges that the US Food and Drug Administration inspected its formulations manufacturing facility at Baddi19-07-2019